February 21, 2022 (London): LumiraDx (Nasdaq: LMDX) announced today that its rapid COVID-19 molecular assay, LumiraDx SARS-CoV-2 RNA STAR Complete, has been successfully validated by Coronavirus Test Device Approvals (CTDA) and received UK Medicines and Healthcare products Regulatory Agency (MHRA) approval. LumiraDx SARS-CoV-2 RNA STAR Complete, developed with proprietary qSTAR technology,...
Concurso de Pintura CNB Para Bacteriólogos y Homólogos.
Para visualizar el formato digital del calendario puedes acceder en el siguiente enlace https://www.lumira.com.co/calendario/
LumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Detects the Omicron Variant
London, UK (January 14, 2022): LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced that results from ongoing testing and monitoring of COVID-19 variants show its SARS-CoV-2 Antigen test detects the Omicron Variant. In-house wet testing with live Omicron virus demonstrated that the LumiraDx SARS-CoV-2 Antigen test detects...
LumiraDx CRP Test Achieves CE Marking
Rapid microfluidic immunofluorescence assay intended for the quantitative determination of C-reactive protein (CRP) in fingerstick, venous whole blood and plasma specimens within a range of 5.0 - 250.0 mg/L Quantitative results in 4 minutes from sample application, aids in fast clinical decision-making at the point of care (POC) Automated CRP...
LumiraDx COVID-19 & Flu A/B Rapid Antigen Test Achieves CE Marking
Rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform intended for the simultaneous detection and differentiation of SARS-CoV-2, influenza A, and influenza B viral antigen Results in 12 minutes or less from sample application, aids in fast clinical decision-making at point of care (POC), helping to inform treatment decisions...
LumiraDx Monitoring of New and Emerging Variants of Concern and Detection of the Omicron Variant
LumiraDx continually monitors for new mutations in the SARS-CoV-2 viral genome as they arise to assess their potential impact on performance of our antigen and molecular products - LumiraDx SARS-CoV-2 Ag test, SARS-CoV-2 Ag Pool test (not available in the US) and LumiraDx SARS-CoV-2 RNA Star Complete and SARS-CoV-2 RNA...
LumiraDx Reports Third Quarter 2021 Financial Results
Strong Revenue Growth and Strategic Progress on Platform, Products and Pipeline London, UK (November 10, 2021), LumiraDx (Nasdaq:LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for the quarter ended September 30, 2021. • Revenue of $109.1M for the three months ended Sept. 30, 2021 and...
LumiraDx to Announce Third Quarter 2021 Financial Results and Host Quarterly Conference Call on November 10
London, UK (November 2, 2021), LumiraDx (Nasdaq:LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its third quarter 2021 financial results on Wednesday, November 10, 2021. On the day of the release, LumiraDx will host a conference call and webcast at 8 AM Eastern Time to...
LumiraDx receives approval for its COVID-19 Antigen Test for use in India
• Test combines sensitivity with speed and is designed to be used in health care settings to aid with rapid diagnosis of COVID-19 • LumiraDx’s microfluidic technology and innovative Point of Care (POC) Platform supports a broad menu of tests with lab-comparable performance, at a low cost, with results available...
LumiraDx Announces FDA EUA Submission for its SARS-CoV-2 & Flu A/B Rapid Antigen Test
• Rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform intended for the simultaneous detection and differentiation of SARS-CoV-2, Influenza A, and Influenza B viral antigen • Results in 12 minutes from sample application, to allow for fast clinical decision-making at point of care (POC) •Available on the same...
